Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Abstract Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patient...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2019-10-01
Collection:Journal for ImmunoTherapy of Cancer
Sujets:
Thymoma
Immunotherapy
Avelumab
Immune-related adverse events
Immunosuppressive therapy
Anti-PD-L1
Accès en ligne:http://link.springer.com/article/10.1186/s40425-019-0723-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires